Deep Dive: Household Contacts, Not Just Moms, Drive Most Infant Hepatitis B Exposure — New Study Challenges Selective Birth Dose

Background

For more than three decades, the CDC recommended that every medically stable newborn receive the hepatitis B vaccine within 24 hours of birth. That universal birth-dose policy was designed as a safety net: hepatitis B virus (HBV) is highly infectious, can survive on surfaces for up to a week, and becomes chronic in more than 90% of infants who are infected early in life. Chronic infection raises the lifetime risk of cirrhosis and liver cancer.

In late 2025 the Advisory Committee on Immunization Practices (ACIP) voted to narrow that recommendation. Under the new CDC guidance, the birth dose is now recommended only for infants whose mothers have active HBV infection or unknown status. Infants born to mothers who test negative are no longer routinely offered the dose before leaving the hospital. The change was part of a broader vaccine-policy overhaul.

What changed this week

At IDWeek 2026 (Washington, DC, 21–24 October), researchers from Kaiser Permanente Northern California presented the first large study that directly examines sources of household HBV exposure in young children.

The retrospective cohort looked at 158,169 children under age 5 living in 131,800 households. Of those children, 2,024 (1.3%) lived with at least one person who had active hepatitis B. That 1.3% rate, applied to roughly 3.63 million U.S. births a year, implies about 47,000 infants annually who could be exposed at home.

Among the exposed children:

• 41.8% (846) were exposed by their birth mother.- 58.2% (1,178) were exposed by someone else in the household — most often an older male relative (median age 44; 76.5% male).

All infants born to HBV-positive mothers received vaccine within seven days. Coverage fell to 93.5% among children with non-maternal household exposure and to 86.7% among unexposed children. The study could not determine how many of the household-exposed children actually became infected, because routine screening of young children is uncommon.

Competing viewpoints

Supporters of the selective birth-dose policy argue that universal vaccination at birth is unnecessary when maternal screening is already performed, that the vaccine carries a small risk of adverse events, and that shared decision-making better respects parental autonomy. They note that overall childhood HBV vaccination rates remain high and that most transmission risk is perinatal.

Critics, including the study authors and the American Academy of Pediatrics, point out that maternal screening alone misses the majority of household exposures. “A child can be exposed to hepatitis B from anyone with an active infection, not just their mother,” said lead author Dr. Karen B. Jacobson. No parent can know the HBV status of every caregiver, grandparent, or visitor. Because infection in infancy carries a 90% risk of chronic disease, the birth dose functions as an anti-cancer intervention for the youngest and most vulnerable.

A separate modeling study presented around the same time estimated that dropping or delaying the universal birth dose could increase chronic HBV infections by 19–83% over 20 years, depending on the strategy adopted.

What to watch next

• Whether CDC or ACIP revisits the selective recommendation in light of the IDWeek data.- State-level responses: some jurisdictions may continue to offer universal birth-dose programs even if federal guidance changes.- Long-term infection and cancer surveillance in cohorts born after the policy shift.- Real-world birth-dose coverage rates in the next National Immunization Survey.

This is editorial context for parents, not medical advice. Talk with your pediatrician or obstetric provider about the hepatitis B birth dose and any household exposure risks.